BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
1. 
The  company Rhône-Poulenc Rorer, France, submitted  on 3 July 1995, to the European  Agency  for 
the  Evaluation  of  Medicinal  Products  (EMEA),  an  application  to  obtain  marketing  authorisation  for 
the medicinal product Rilutek in accordance with the Centralised Procedure falling within the scope of 
Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
Dr. D. Jefferys 
Co-Rapporteur:  Dr. P. Le Courtois 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The  Co-Rapporteur’s  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on  
25 September 1995. 
The  Rapporteur’s  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on 
27 September 1995. 
The  CPMP  during  their  meeting  on  17-19  October  1995,  considered  the  methodological 
problems concerning design, execution and statistical analysis of the clinical part and proposed 
an expert meeting on the 15 November 1995, with experts on neurology and statistics. A list of 
points to be answered by the company in advance of that meeting was also agreed and sent to 
the company on 20 October 1995. 
A  summary  of  the  current  status  of  methodological  issues  relating  to  efficacy  was  issued  on 
27 November 1995. 
The CPMP final consolidated list of comments was sent to the company on 30 November 1995. 
The  company  submitted  the  responses  to  the  consolidated  CPMP  list  of  comments  on 
22 December 1995. 
A Rapporteur/Co Rapporteur  expert  meeting  was  held  on the 15 January 1996, to  finalise the 
assessment report on the company’s responses. 
The  Rapporteur’s  “Responses’  assessment  report”  was  circulated  to  all  CPMP  Members  on  
16 January 1996. 
The Co-Rapporteur’s “Responses’ assessment report” was circulated to all CPMP Members on 
19 January 1996. 
The CPMP in their meeting on 13-15 February 1996 discussed the recommendations presented 
by the Rapporteur and Co-Rapporteur. A hearing with the company took place on 13 February 
1996 to address the final outstanding issues. 
Amendments  were  made  accordingly  on  the  Summary  of  Product  Characteristics  and  User 
Package Leaflet texts. 
The CPMP on 14 February 1996 adopted a favourable opinion by scientific consensus. 
1/1 

EMEA 2004 
 
 
 
 
 
 
